ORYL Photonics introduces the ORYL F1, a novel automated laser-based platform for the measurement of solubility and aggregation of drug molecules in the Life Science industry. This is a significant achievement for the fast-growing Swiss company and for the solubility and aggregation community. The laboratory instrument enables researchers to make faster decisions and gain a deeper understanding of

Enrollment underway in CHAPTER-3, a pivotal Phase 3 study of deucrictibant for prophylaxis of HAE attacks; topline data expected in 2H2026 Attack dataset continues to accumulate in RAPIDe-3, a pivotal Phase 3 study of deucrictibant for the on-demand treatment of HAE attacks, strengthening confidence in clinical timelines TQT study waivers received from FDA for both deucrictibant extended-release f

First characterization of tRNA modifications that dysregulate mRNA stability of signaling pathways in cancer Umlaut.bio is an EMBL spin-off creating cancer and autoimmune therapeutics through small molecule inhibition of tRNA modifications With its senior executive team and a world-class advisory board, Umlaut.bio has started operations funded by HTGF, LBBW Venture Capital and L-Bank through the I